Synedica Retatrutide 40mg Injection Pen (original)

Synedica Retatrutide 40 mg Injection Pen Regulatory status: Retatrutide is an investigational GLP-1/GIP/glucagon receptor agonist. It is not authorised as a medicinal product in the EU or elsewhere. The manufacturer supplies it for laboratory research only, not for human or animal use. No dosing information for human use is provided. Product details Brand: Synedica® Form: pre-filled pen Composition and package contents (as stated by the manufacturer) Retatrutide – 40 mg per pen 1 × Synedica Retatrutide pen 12 × disposable 32G / 4 mm needles 1 × instruction booklet Product details are reproduced from the manufacturer's information and have not been independently verified against the physical label.